India-China standoff unlikely to hit output of pharma companies
(WorldNews China)

The Indian pharmaceutical industry has enough stock of raw materials, and the delays in clearing Chinese-origin shipments by customs across ports will not disrupt production. Domestic drugmakers, which import about two-thirds of their active pharmaceutical ingredients (APIs) from China, witnessed severe supply disruptions since March due to the covid-19-led lockdown in Wuhan, and other pharma...